PURPOSE: Calculating the absorbed dose is important for the determination of risk and therapeutic benefit of internal radiation therapy. The aim of this study was to perform image-based absorbed dose calculation for critical organs during the first cycle of [(177)Lu]DKFZ-PSMA-617 therapy in a small cohort of patients with metastatic prostate cancer. PROCEDURES: Nine patients with a history of prostate cancer documented by histopathology and radiologic evidence of metastatic diseases underwent radioligand therapy with [(177)Lu]DKFZ-PSMA-617. Conjugated planar whole-body scintigraphies acquired at 0.5, 24, 48, 72, and 168 h post-injection were analyzed by regions of interest, and time-activity curves were generated for various organs. Cumulated activities and residence times were calculated by bi-exponential fit of the time-activity curves. Mean absorbed doses were finally estimated using OLINDA/EXM1.1™. Additionally, the uncertainty when omitting the last measurement (168 h p.i.) was studied. RESULTS: The following mean absorbed doses were calculated: 2.82 mGy/MBq for the lacrimal glands, 0.72 mGy/MBq for the salivary glands, 0.53 mGy/MBq for the kidneys, and 0.42 mGy/MBq for the nasal mucous membrane. Omitting the last measurement resulted in a mean deviation of 10 to 25 % for absorbed dose values as compared to the ones received by analyzing all measurements. CONCLUSION: Absorbed organ doses of [(177)Lu]DKFZ-PSMA-617 therapy are not likely to be critical for kidneys, salivary glands, and the nasal mucous membrane. The lacrimal glands may represent the dose-limiting organs. Whole-body scintigraphy appears sufficient for dose estimation, but late measurements are mandatory, if accurate dose calculation is required.
PURPOSE: Calculating the absorbed dose is important for the determination of risk and therapeutic benefit of internal radiation therapy. The aim of this study was to perform image-based absorbed dose calculation for critical organs during the first cycle of [(177)Lu]DKFZ-PSMA-617 therapy in a small cohort of patients with metastatic prostate cancer. PROCEDURES: Nine patients with a history of prostate cancer documented by histopathology and radiologic evidence of metastatic diseases underwent radioligand therapy with [(177)Lu]DKFZ-PSMA-617. Conjugated planar whole-body scintigraphies acquired at 0.5, 24, 48, 72, and 168 h post-injection were analyzed by regions of interest, and time-activity curves were generated for various organs. Cumulated activities and residence times were calculated by bi-exponential fit of the time-activity curves. Mean absorbed doses were finally estimated using OLINDA/EXM1.1™. Additionally, the uncertainty when omitting the last measurement (168 h p.i.) was studied. RESULTS: The following mean absorbed doses were calculated: 2.82 mGy/MBq for the lacrimal glands, 0.72 mGy/MBq for the salivary glands, 0.53 mGy/MBq for the kidneys, and 0.42 mGy/MBq for the nasal mucous membrane. Omitting the last measurement resulted in a mean deviation of 10 to 25 % for absorbed dose values as compared to the ones received by analyzing all measurements. CONCLUSION: Absorbed organ doses of [(177)Lu]DKFZ-PSMA-617 therapy are not likely to be critical for kidneys, salivary glands, and the nasal mucous membrane. The lacrimal glands may represent the dose-limiting organs. Whole-body scintigraphy appears sufficient for dose estimation, but late measurements are mandatory, if accurate dose calculation is required.
Authors: Neil H Bander; Matthew I Milowsky; David M Nanus; Lale Kostakoglu; Shankar Vallabhajosula; Stanley J Goldsmith Journal: J Clin Oncol Date: 2005-04-18 Impact factor: 44.544
Authors: Valerie Humblet; Rena Lapidus; Larry R Williams; Takashi Tsukamoto; Camilo Rojas; Pavel Majer; Bunda Hin; Shunsuke Ohnishi; Alec M De Grand; Atif Zaheer; Jürgen T Renze; Akira Nakayama; Barbara S Slusher; John V Frangioni Journal: Mol Imaging Date: 2005 Oct-Dec Impact factor: 4.488
Authors: Martina Benešová; Martin Schäfer; Ulrike Bauder-Wüst; Ali Afshar-Oromieh; Clemens Kratochwil; Walter Mier; Uwe Haberkorn; Klaus Kopka; Matthias Eder Journal: J Nucl Med Date: 2015-04-16 Impact factor: 10.057
Authors: Chad M Bingham; Alexandra Castro; Tony Realini; John Nguyen; Jeffery P Hogg; Jennifer A Sivak-Callcott Journal: Ophthalmic Plast Reconstr Surg Date: 2013 May-Jun Impact factor: 1.746
Authors: Sangeeta R Banerjee; Catherine A Foss; Mark Castanares; Ronnie C Mease; Youngjoo Byun; James J Fox; John Hilton; Shawn E Lupold; Alan P Kozikowski; Martin G Pomper Journal: J Med Chem Date: 2008-07-19 Impact factor: 7.446
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Tobias Maurer; Gregor Weirich; Margret Schottelius; Martina Weineisen; Benjamin Frisch; Asli Okur; Hubert Kübler; Mark Thalgott; Nassir Navab; Markus Schwaiger; Hans-Jürgen Wester; Jürgen E Gschwend; Matthias Eiber Journal: Eur Urol Date: 2015-05-06 Impact factor: 20.096
Authors: Hojjat Ahmadzadehfar; Kambiz Rahbar; Stefan Kürpig; Martin Bögemann; Michael Claesener; Elisabeth Eppard; Florian Gärtner; Sebastian Rogenhofer; Michael Schäfers; Markus Essler Journal: EJNMMI Res Date: 2015-06-20 Impact factor: 3.138
Authors: Maria Larsson; Peter Bernhardt; Johanna B Svensson; Bo Wängberg; Håkan Ahlman; Eva Forssell-Aronsson Journal: EJNMMI Res Date: 2012-09-24 Impact factor: 3.138
Authors: Sangeeta Ray Banerjee; Vivek Kumar; Ala Lisok; Donika Plyku; Zora Nováková; Mary Brummet; Bryan Wharram; Cyril Barinka; Robert Hobbs; Martin G Pomper Journal: J Nucl Med Date: 2018-09-20 Impact factor: 10.057
Authors: Jens Kurth; Bernd Joachim Krause; Sarah M Schwarzenböck; Carina Bergner; Oliver W Hakenberg; Martin Heuschkel Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-03 Impact factor: 9.236
Authors: Donika Plyku; Esther Mena; Steven P Rowe; Martin A Lodge; Zsolt Szabo; Steve Y Cho; Martin G Pomper; George Sgouros; Robert F Hobbs Journal: Eur J Nucl Med Mol Imaging Date: 2018-02-19 Impact factor: 9.236
Authors: Xiaoxi Ling; Joseph D Latoche; Cindy J Choy; Brenda F Kurland; Charles M Laymon; Yijen Wu; Nathan Salamacha; Ding Shen; Jonathan J Geruntho; Lora H Rigatti; Hillarie P Windish; Beatrice Langton-Webster; Clifford E Berkman; Carolyn J Anderson Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: Benedikt Feuerecker; Maythinee Chantadisai; Anne Allmann; Robert Tauber; Jakob Allmann; Lisa Steinhelfer; Isabel Rauscher; Alexander Wurzer; Hans-Jürgen Wester; Wolfgang A Weber; Calogero d'Alessandria; Matthias Eiber Journal: J Nucl Med Date: 2021-09-16 Impact factor: 11.082
Authors: John Violet; Shahneen Sandhu; Amir Iravani; Justin Ferdinandus; Sue-Ping Thang; Grace Kong; Aravind Ravi Kumar; Tim Akhurst; David A Pattison; Alexis Beaulieu; Jennifer Mooi; Ben Tran; Christina Guo; Victor Kalff; Declan G Murphy; Price Jackson; Peter Eu; Mark Scalzo; Scott Williams; Rodney J Hicks; Michael S Hofman Journal: J Nucl Med Date: 2019-11-15 Impact factor: 11.082